Searched for
HUMIRA
AbbVie in advanced talks to buy cancer drugmaker revolution medicines, shares jump nearly 30%AbbVie is in advanced talks to buy Revolution Medicines, a cancer drug company. The news pushed Revolution Medicines shares sharply higher....- Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in JapanAdalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylos...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Looking at additional fundraisers to further reduce acquisition debt: Kiran Mazumdar Shaw, BioconNo, there was no understanding to have operational involvement, but we had offered a board seat and that will remain and it is for Serum to...
- Buy Biocon, target price Rs 375: JM FinancialBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 28934.46 Crore) operating in Pharmaceuticals secto...
- AbbVie plans product launches in India from global portfolioIn addition, the drug maker is also considering making India part of its global Phase-3 clinical trials for potential therapies under devel...
- Scientists create antibody that claims to defeat coronavirus in labMore research is needed to see whether the findings are confirmed in a clinical setting and how precisely the antibody defeats the virus.
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Glenmark launches biosimilar Adalimumab in IndiaGlenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it t...
- Hetero launches HumiraTM biosimilar in IndiaThe product will be marketed by Hetero Healthcare under the brand name ‘MaburaTM’ in India, the company said.
- Biologics enter top selling drugs’ listBiologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out o...
- Glenmark Pharma wins patent suit against Abbott; stock gainsGlenmark Pharamceuticals had filed a pre-grant opposition in September 2008 after Abott was granted a patent to Humira drug.
- We hope to launch 2 original drugs by 2020: Cadila chairman Pankaj PatelIn biosimilars, EU has already laid out the path, the US has issued many guidelines and the pathway there is evolving rapidly.
- Zydus Cadila launches biosimilar of AbbVie's Humira in IndiaZydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator...
- Strides invests in US-based biosimilar companyStrides Arcolab has invested in Oncobiologics Inc, a privately held US-based drug company focussed on biosimilar and novel biologic drug re...
- Abbott to buy Latin American drugmaker CFR in $2.9 billion dealAbbott Lab would acquire Chile's CFR Pharma SA in a two-part, $2.9 bn deal, to double its branded generic drugs portfolio & expand in fast-...
- Biocon-Mylan partnership has a potential of $33 billion from biosimilar drugsTwo years after announcing a JV with Mylan, Biocon has revealed the potential of its drugs under the biologics deal with Mylan.
- Abbott cuts 1,900 jobs from US drug businessAbbott Laboratories said Wednesday it would eliminate 1,900 employees to keep profits up, indicating that one of the pharmaceutical industr...
- J&J unit wins $1.67 billion verdict vs Abbott LabsA unit of Johnson & Johnson said Monday that a federal jury has ordered Abbott Laboratories to pay $1.67 billion in a patent infringement s...
- New data backs UCB drug for arthritisNew clinical data endorses the efficacy of UCB SA's experimental drug Cimzia given either fortnightly or monthly, researchers said on Thurs...
Load More
